Sponsor content
7 result(s) found, displaying 1 to 7
-
Apr-2026Prescription medicine evaluationActive ingredient: zanidatamab.
-
Apr-2026Prescription medicine evaluationActive ingredient: tislelizumab.
-
Designation or determinationProvisional determination
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRUKINSA zanubrutinib 160 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TEVIMBRA tislelizumab 100 mg/10 mL concentrated injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BRUKINSA zanubrutinib 80 mg capsule bottle.